Clinical trials: Endometrial Intraepithelial Neoplasia
Neoplasms
Endometrial Cell Collection With the PadKit
All patients will be provided with a Preprogen Pad to be worn for 4-6 hours to collect cells shed by the endometrium. After the kit is returned to the Preprogen laboratory, a brief survey will be completed.
- Trial name
- NCT06464107
- Testing
- PadKit™ from Preprogen
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Hackensack Meridian Health
Endometrial Cancer, Endometrial Cancer Stage I
SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer
SHAPE-ENDO is a single-center, open-label, pilot randomized clinical trial conducted at Hospital Universitari de Bellvitge in Barcelona, Spain.
- Conditions
- Endometrial Cancer, Endometrial Cancer Stage I, Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I, Atypical Endometrial Hyperplasia
- Trial name
- SHAPE-ENDO (NCT07462663)
- Testing
- GLP-1 Receptor Agonist, Levonorgestrel IUD (Lng-IUD), Oral Progestins
- Volunteers
- 80 people
- Sponsor
- Hospital Universitari de Bellvitge
Atypical Endometrial Hyperplasia, Endometrial Carcinoma Stage I
Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia
To explore the treatment efficacy of medroxyprogesterone acetate plus atorvastatin in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) for conservative treatment.
- Trial name
- NCT05675787
- Testing
- Medroxyprogesterone acetate + Atorvastatin
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Peking University People's Hospital
Obesity, Overweight
Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer
This is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of mazdutide combined with a levonorgestrel-releasing intrauterine…
- Conditions
- Obesity, Overweight, Atypical Endometrial Hyperplasia, Endometrial Carcinoma Stage I
- Trial name
- MELIA (NCT07781150)
- Testing
- Mazdutide(Dual GLP-1R/GCGR Agonist), Levonorgestrel-releasing intrauterine system
- Where
- 6 sites in China
- Volunteers
- 128 people
- Sponsor
- Tongji Hospital
Endometrioid Endometrial Adenocarcinoma
A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia
This study will explore the use of glucagon-like peptide 1 receptor agonist (GLP-1RA) used concurrently with levonorgestrel intrauterine device in patients with poor surgical candidacy for a hysterectomy or patients who are…
- Trial name
- NCT07107334
- Testing
- Glucagon-like peptide 1 receptor agonist
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Florida
Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia
Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer
The goal of this clinical trial is to learn if a combination treatment of a hormonal intrauterine device (LNG-IUD), semaglutide, and a structured weight loss program can treat endometrial atypical hyperplasia or grade 1…
- Conditions
- Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Cancer Stage I, Endometrial Cancer
- Trial name
- SWIFT (NCT07820358)
- Testing
- Semaglutide (Wegovy) weekly injection, LNG-IUD (Progestin), Structured Weight Loss Program
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- The Methodist Hospital Research Institute
Grade 1 Endometrial Endometrioid Carcinoma, Endometrial Intraepithelial Neoplasia
Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer
This single-arm study will evaluate the feasibility, safety, and preliminary efficacy of tirzepatide in combination with standard levonorgestrel intrauterine device (LNG-IUD) therapy in patients with endometrial intraepithelial…
- Conditions
- Grade 1 Endometrial Endometrioid Carcinoma, Endometrial Intraepithelial Neoplasia, Metabolic Comorbidities
- Trial name
- TIDE (NCT07812636)
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Milton S. Hershey Medical Center
Endometrial Cancer, Cervical Cancer
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human…
- Conditions
- Endometrial Cancer, Cervical Cancer, Atypical Endometrial Hyperplasia, Cervical Dysplasia
- Trial name
- ECHO (NCT05051722)
- Testing
- Vaginal Fluid Collection, Blood Collection
- Where
- 25 sites in United States
- Volunteers
- 3,110 people
- Sponsor
- Mayo Clinic
Uterine Bleeding, Uterine Cancer
Measurement of Urinary Hormones in Patients With Abnormal Uterine Bleeding to Study Uterine Cancer Progression
The investigators will obtain urine hormone results and validated menstrual bleeding score from people experiencing abnormal uterine bleeding. The investigators will evaluate satisfaction and ease of use of Mira monitor.
- Conditions
- Uterine Bleeding, Uterine Cancer, Uterine Neoplasms, Endometrial Cancer
- Trial name
- MIRA (NCT07581288)
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University of British Columbia
Atypical Endometrial Hyperplasia, Endometrial Carcinoma
Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate
The purpose of this trial is to study the efficacy, toxicity, and tolerability of a standard hormonal regimen of Megestrol Acetate (Megace) in the treatment of Atypical Endometrial Hyperplasia or well to moderately differentiated…
- Trial name
- NCT00483327
- Testing
- Megestrol Acetate
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- NYU Langone Health
Endometrial Adenocarcinoma, Endometrial Hyperplasia
Surgical and Obstetric Outcomes in Endometrial Adenocarcinoma and Atypical Endometrial Hyperplasia With Conservative Treatment
This observational study aims to evaluate the obstetric and oncological outcomes of patients diagnosed with endometrial adenocarcinoma (EAC) or atypical endometrial hyperplasia (AEH) who underwent conservative treatment at the…
- Conditions
- Endometrial Adenocarcinoma, Endometrial Hyperplasia, Fertility Preservation, Conservative Treatment Therapy
- Trial name
- CHOICE (NCT07077876)
- Testing
- Hysteroscopic Resection and Hormonal Therapy
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Endometrial Hyperplasia
Efficacy of LNG-IUS for Treatment of Non-atypical Endometrial Hyperplasia in Perimenopausal Women
The purpose of this study is to compare the efficacy of the Levonorgestrel releasing Intrauterine System (Mirena) and Norethisterone Acetate for treatment of non-atypical endometrial hyperplasia in perimenopausal women.
- Trial name
- NCT01499602
- Testing
- LNG-IUS; Mirena; Bayer Schering Pharma Oy, Finland, Norethisterone Acetate tablets
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Mansoura University
Endometrial Cancer, Endometrial Hyperplasia With Atypia
Endometrial Changes in Breast Cancer Women.
This is a prospective observational multicentric study. The aim is to evaluate the incidence of endometrial cancer and endometrial atypical hyperplasia in patients with previous breast cancer, treated with different adjuvant…
- Conditions
- Endometrial Cancer, Endometrial Hyperplasia With Atypia, Breast Cancer, TAM
- Trial name
- NCT05717634
- Testing
- Hysteroscopy
- Where
- Italy
- Volunteers
- 829 people, healthy volunteers welcome
- Sponsor
- Regina Elena Cancer Institute
Endometrial Hyperplasia Without Atypia
Vaginal Micronized Progesterone Versus Levonorgestrel for Treatment of Non-atypical Endometrial Hyperplasia
The purpose of this study is to compare the efficacy of the vaginal micronized progesterone and Levonorgestrel-releasing Intrauterine System for treatment of non-atypical endometrial hyperplasia in premenopausal women.
- Trial name
- NCT03992937
- Testing
- Vaginal Micronized Progesterone, Levonorgestrel-Intrauterine System
- Where
- Turkey (Türkiye)
- Volunteers
- 132 people
- Sponsor
- Kocaeli University
Atypical Endometrial Hyperplasia
Megestrol Acetate Plus LNG-IUS in Young Women With Endometrial Atypical Hyperplasia
To see if megestrol acetate plus Levonorgestrel-releasing intrauterine system (LNG-IUS) will not be inferior to returning the endometrial tissue to a normal state than megestrol acetate or LNG-IUS alone in patients with…
- Trial name
- NCT03241888
- Testing
- Megestrol Acetate, Levonorgestrel-releasing Intrauterine System(LNG-IUS)
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Fudan University
Atypical Endometrial Hyperplasia, Stage I Uterine Corpus Cancer AJCC v7
Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer
This phase II trial studies how well levonorgestrel-releasing intrauterine system works in treating patients with complex atypical hyperplasia or grade I endometrial cancer.
- Conditions
- Atypical Endometrial Hyperplasia, Stage I Uterine Corpus Cancer AJCC v7, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Uterine Corpus Cancer AJCC v7
- Trial name
- NCT00788671
- Testing
- Laboratory Biomarker Analysis, Levonorgestrel-Releasing Intrauterine System, Quality-of-Life Assessment
- Where
- 7 sites in United States
- Volunteers
- 69 people
- Sponsor
- M.D. Anderson Cancer Center
Serous Endometrial Intraepithalial Carcinoma, SEIC
Serous Endometrial Intraepithelial Carcinoma (SEIC): Prospective Registration Study
Background: Serous endometrial intra-epithelial carcinoma (SEIC) is a rare condition affecting the lining of the uterus. It's a pre-cancerous change that might lead to cancer if not treated.
- Trial name
- SEIC (NCT06677242)
- Testing
- Blood sample (serum) for circulating tumor DNA and cervical smear for genome-wide methylation sequencing
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- Erasmus Medical Center
Atypical Endometrial Hyperplasia, Endometrial Cancer
Intrauterine Injection of Type III Collage in FST of EC/AEH
The goal of this clinical trial is to learn if intrauterine injection of "Recombinant Humanized Type III Collagen Lyophilized Fibers" works to treat endometrial cancer or atypical hyperplasia in patients seeking…
- Trial name
- 2026ColECFerSp (NCT07377734)
- Testing
- Recombinant Humanized Type III Collagen Lyophilized Fibers + High-dose Progestin, High-dose Progestin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Wang Jianliu
Atypical Endometrial Hyperplasia
LVN- IUS Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia
This randomized controlled trial is aimed to compare the efficacy between Megestrol acetate (MA) and the levonorgestrel intrauterine system (LNG-IUD) regarding the ability and duration to produce complete regression for cases…
- Trial name
- NCT04385667
- Testing
- levonorgestrel intrauterine system (LNG-IUD), Oral Megesterol 160 mg daily
- Where
- Egypt
- Volunteers
- 143 people
- Sponsor
- Zagazig University
Atypical Endometrial Hyperplasia, Obese
Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia
To investigate the efficacy of liraglutide plus megestrol acetate in obesity patients with atypical endometrial hyperplasia (AEH)
- Conditions
- Atypical Endometrial Hyperplasia, Obese, Fertility Issues
- Trial name
- NCT04683237
- Testing
- Liraglutide Injection, Megestrol Acetate 160 MG
- Sponsor
- Xiaojun Chen